| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
26 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-113 |
| Cash Flow (TTM) (Millions $) |
9 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Kythera Biopharmaceuticals Inc. was a biopharmaceutical company that specialized in the development and commercialization of prescription products for aesthetic medicine. The company was founded in 2005 and was headquartered in Westlake Village, California.
Kythera Biopharmaceuticals focused on developing products that targeted specific areas of aesthetic concern, such as submental fullness (double chin) and scalp hair. One of their notable products was Kybella, an injectable drug that was approved by the U.S. Food and Drug Administration (FDA) for reducing submental fat.
The company conducted extensive research and clinical trials to ensure the safety and effectiveness of their products. They collaborated with dermatologists, plastic surgeons, and other healthcare professionals to develop innovative solutions for aesthetic medicine.
In 2015, Kythera Biopharmaceuticals was acquired by Allergan, a multinational pharmaceutical company. Following the acquisition, Kybella became a part of Allergan's portfolio of aesthetic products.
Overall, Kythera Biopharmaceuticals was dedicated to providing cutting-edge treatments for aesthetic concerns and improving the lives of patients seeking non-surgical alternatives for cosmetic enhancements.
|
%